Tuesday, May 19, 2020 12:14:17 PM
1) The headline refers to the BS Level-3 Facility:
"Innovation Pharmaceuticals’ Brilacidin Reduces Viral Titer of SARS-CoV-2 (COVID-19) by 75 percent After Only 1 Hour of Preincubation in In Vitro Study at BSL-3 Facility."
This means that the BSL Facility is still testing as a vaccine, further shown by the statement "Additional time-dependent and concentration-dependent experiments are underway to further delineate Brilacidin’s virucidal properties against SARS-CoV-2."
2) The RBL (different than the BSL-3) is still testing multiple avenues, including a vaccine:
"Brilacidin anti-SARS-CoV-2 research is part of ongoing antiviral studies that are being conducted at a U.S. Regional Biocontainment Laboratory (RBL). An earlier 16-hour post-infection experiment, in VERO cells, showed Brilacidin exhibited a dose-dependent reduction in SARS-CoV-2 infectious viral titers."
"The Company is encouraged by Brilacidin’s considerable antiviral potential and believes that its use as a possible potent prophylactic and therapeutic antiviral agent for SARS-CoV-2, and other viruses, is warranted."
3) There's a third entity (Public Institute of Health? The "University"? Some other entity?) with which the company engaged that have decided the best approach is as a therapeutic, possibly because the other two labs are already/still doing vaccine testing.
"Separately, the Company and laboratory researchers (from a different testing facility) agreed that Brilacidin as a vaccine would not be studied further at this time."
That paragraph goes on to say that the company is prioritizing B's development as a treatment (therapeutic) and "is taking steps to rapidly advance B into human trials". No partner entity is provided for this step, it appears IPIX is still pursuing and reviewing the best way to achieve this.
I read this PR as updates on these three different avenues with a couple others potential entities (PIH, University) still awaiting an update. This is very positive imo as it shows B is still in play both as a vaccine (solo or as an adjuvant) AND as a therapeutic.
Recent IPIX News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 01:30:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/05/2023 09:25:58 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 09:05:44 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/15/2023 01:00:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2023 08:15:25 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/28/2023 01:00:08 PM
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM